Antidepressant patents: 1995 - 1997

Bibliography

• KATON W: The epidemiology of depression in medical care. Intern. J. Psycho]. Med. (1987) 17:93–112.
   PubMed Web of Science ®Google Scholar
• REGIER DA, BOYD JH, BURKE JD et al.: One-month prevalence of mental disorders in the United States: based on five epidemiological catchment area sites. Arch. Gen. Psychiatry (1988) 45:977–986.
   PubMed Web of Science ®Google Scholar
• ASBERG M, SCHALLING D, TRASKMAN-BENDZ L et al.: Psychobiology of suicide, impulsivity and related phe-nomena. In: Psychopharmacology. The Third Generation of Progress. Meltzer et al. (Eds.), Raven Press, New York (1987) 655–668.
   Google Scholar
• GREENBERG PE, STIGLIN LE, FINKELSTEIN SN, BERNDT JR: The economic burden of depression in 1990.1 Clin. Psychiatry (1993) 54:405–418.
   PubMed Web of Science ®Google Scholar
• KAPUR S, MIECZKOWSKI T, MANN JJ: Antidepressant medications and the relative risk of suicide attempt and suicide. JAMA (1992) 268(24):3441–3445.
   PubMed Web of Science ®Google Scholar
• ACNP TASK FORCE: Neuropsychopharmacol. (1993) 8:177.
   Google Scholar
• FINLEY PR: Selective serotonin re-uptake inhibitors: pharmacological profiles and potential therapeutic distinctions. Annals of Pharmacotherapy (1994) 28: 1359–1369.
   PubMed Web of Science ®Google Scholar
• •A review of pharmacological profiles, pharmacokinetics and clinical trials of fluvoxamine, fluoxetine, sertraline and paroxetine.
   Google Scholar
• CUSAK B, NELSON A, RICHELSON E: Binding of antide- to human brain receptors: focus on newer generation compounds. Psychopharmacology (1994) 114:559–565.
   PubMedGoogle Scholar
• PRESKORN SH, JANICAK PG, DAVIS JM, AYD FJ: Advances in the pharmacotherapy of depressive disorders. In: Principles and Practice of Psychopharmacotherapy. Janicak PG (Ed.). Williams & Wilkins, New York (1995).
   Google Scholar
• NORMAN TR, LEONARD BE: Fast-acting antidepres-sants: can the need be met. CNS Drugs (1994) 2(2):120–131.
   Google Scholar
• SCHWEIZER E, THIELEN RJ, FRAZER A: Venlafaxine: a novel antidepressant compound. Exp. Opin. Invest. Drugs (1997) 6(0:65–78.
   PubMedGoogle Scholar
• HEYDORN WE: Mirtazapine: a novel antidepressant compound currently undergoing clinical evaluation. Exp. Opin. Invest. Drugs (1995) 4(10945–954.
   Google Scholar
• NIERENBERG AA, FEIGHNER JP, RUDOLPH RR, COLE JO: Venlafaxine for treatment-resistant depression. Ab-stracts & Proceedings Summary 147th Annual Meeting American Psychiatric Association (1995) 97–98.
   Google Scholar
• ARTIGAS F, PEREZ V, ALVAREZ E: Pindolol induces a improvement of depressed patients treated with serotonin re-uptake inhibitors. Arch. Gen. Psychiat. (1994) 51 (3):248–251.
   PubMedGoogle Scholar
• ••A report of a small clinical trial providing strong evidence forthe hypothesis that 5-HT1A autoreceptors may be the key to achieving rapid antidepressant action.
   Google Scholar
• PEREZ V, GILABERTE I, FARIES D, ALVAREZ E, ARTIGAS F:, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepres-sant treatment. Lancet (1997) 349:1594–1597.
   PubMed Web of Science ®Google Scholar
• ••Report of a placebo-controlled trial confirming that a 5-HT1Aautoreceptor antagonist can enhance the efficacy of an SSRI.
   Google Scholar
• SCHUTSKE GM: Recent developments in serotonin re-uptake inhibitors. Exp. Opin. Ther. Patents (1994) 4 (0335–341.
   Google Scholar
• DE VRY J: 5-HT1A receptor agonists: Recent develop-ments and controversial issues. Psychopharmacology (1995) 121 (1) :1–26.
   PubMedGoogle Scholar
• LESCH KP, HOH A, SCHULTE HM, OSTERHEIDER M, MUL-LER T: Long-term fluoxetine decreases 5-HT1A respon-sivity in obsessive-compulsive disorder. Psychopharmacology (1991) 105 (3) :415–420.
   PubMedGoogle Scholar
• BLIER P, SELETTI B, BOUCHARD C, ARTIGAS F, DE MON-TIGNY C: Functional evidence for the differential re-sponsiveness of pre- and postsynaptic 5-HT1A receptors in rat brain. Soc. Neurosci. Abst. (1994) 20:1540.
   Google Scholar
• DE VRY J: 5-HTIA receptors in psychopathology and the mechanism of action of clinically effective thera-peutic agents. Drug News and Perspectives (1996) 9(5) 270–280.
   Google Scholar
• ••A review of the significance of 5-HTIA receptors to stress-related behavioural disorders.
   Google Scholar
• BARTOSZYK GD, HEGENBART R, ZIEGLER H: EMD 68843, a serotonin re-uptake inhibitor with selective presynaptic 5-HT1A receptor agonistic properties. Eur. Pharmacol (1997) 322:147–153.
   PubMed Web of Science ®Google Scholar
• HARTIG PR, HOYER D, HUMPHREY PPA, MARTIN GR: Alignment of receptor nomenclature with the human genome: classification of 5-HT0 and 5-HT1u receptor subtypes. Trends Pharmacol. Sci. (1996) 17:103–105.
   PubMed Web of Science ®Google Scholar
• ROLLEMA H, CLARKE T, SPROUSE JS, SCHULZ DW: Com-bined administration of a 5-HT1u antagonist and a 5-HT re-uptake inhibitor synergistically increases 5-HT release in guinea-pig hypothalamus in vivo. J. Neurochem. (1996) 67:2204–2207.
   PubMed Web of Science ®Google Scholar
• YATES M, LEAKE A, CANDY JM, FAIRBAIRN IG, FERRIER IN: 5-11T2 receptor changes in major depression. Biol. Psychiatry (1990) 27:19–32.
   Google Scholar
• ANDRADE R, ARANEDA R: 5-11T2 and 5-HT1A receptors mediate opposing responses on membrane excitabil-ity in rat association cortex. Neuroscience (1991) 40:399–412.
   PubMedGoogle Scholar
• GOODNICK PJ, BENITEZ A: New antidepressant agents:recent pharmacological developments leading to im-proved efficacy. Exp. Opin. Invest. Drugs (1995) 4(10935–943.
   Google Scholar
• HEYDORN WE: Nefazodone: a summary of the available data on a new antidepressant agent. Exp. Opin. Invest. Drugs (1995) 4(2):131–137.
   Google Scholar
• REYNOLDS LS, BRASELTON JP, SPROUSE JS et al: In vivo profile of CP-93393: evidence of combined 5-HT1A ago-nist and ay antagonist activities. Soc. Neurosci. (1995) 21:Abstract 827.5.
   Google Scholar
• KERRIGAN F, CHEETHAM SC, JACKSON H et al.: Novel 5-amino-4-(4-arylpiperazin-1-ylmethy0 pyrazoles with high affinity for 5-HT1A and an receptors as potential antidepressants. 213th ACS National Meeting (1997) Poster 26.
   Google Scholar
• BORSINI F, CESANA R, KELLY J et al.: BIMT-17: a putative antidepressant with a fast onset of action? Psychophar-macol. (1997) 134:378-386.
   Google Scholar
• GLENNON RA, WESTKAEMPER RB: 5-HT1u receptors: a serotonin receptor population for the 1990s. Drug News Perspect. (1993) 6:390–405.
   Google Scholar
• PAUWELS PJ, COLPAERT FC: The 5-HT1u receptor an-tagonist GR-127935 is an agonist at cloned human 5-HTiDa receptor sites. Neuropharmacology (1995) 34:235–237.
   PubMedGoogle Scholar
• WATSON JM, BURTON MJ, PRICE GW et al.: GR-127935acts as a partial agonist at recombinant human 5-HT1cia and 5-HT1up receptors. Eur.J. Pharmacol. (1996) 314:365–372.
   PubMed Web of Science ®Google Scholar
• HALAZY S, LAMOTHE M, JORAND-LEBRUN C: 5-HT1si1D antagonists and depression. Exp. Opin. Ther. Patents (1997) 7(4):339–352.
   Web of Science ®Google Scholar
• ••A thorough review of the development of 5-HT1B/IDantagonists.
   Google Scholar
• ADHAM et al.: Cloning and characterisation of a recom-binant guinea-pig 5-HT1F receptor. Am. Soc. Neurosci. (1996) 22. Abstract 528.9.
   Google Scholar
• PIGOTT TA, HILL JL, GRADY TA et al.: A comparison of the behavioural effects of oral versus intravenous mCPP administration in OCD patients and the effects of metergoline prior to iv. mCPP. Biol. Psychiatry (1993) 33:3–14.
   PubMed Web of Science ®Google Scholar
• HOLLANDER E, DECARIA C, GULLY R et al.: Effects of chronic fluoxetine treatment on behavioural and neu-roendocrine responses to meta-chlorophenylpiper-azine in obsessive-compulsive disorder. Psychiatry Res. (1991) 36:1.
   PubMedGoogle Scholar
• FORBES IT, HAM P, BOOTH DH et al.: 5-Methyl-1-(3-pyridylcarbamoyfi -1,2,3,5-tetrahydropyrrolo [2,3-4in-dole: a novel 5-11T2cas receptor antagonist with im-proved affinity, selectivity and oral activity. J. Med. Chem. (1995) 38(14):2524–2530.
   PubMedGoogle Scholar
• BOES M, JENCK F, MARTIN JR et al.: 5-11T2c Receptor an-tagonists: synthesis, pharmacology and therapeutic potential. 214th ACS National Meeting (1997). Lecture 267.
   Google Scholar
• LEYSEN D, KELDER J: The search for selective 5-11T2cagonists as potential antidepressants. 9th RSC-SCI Me-dicinal Chemistry Symposium, Cambridge UK (1997). Lec-ture 4.
   Google Scholar
• EGLEN RM, WONG EHF, DUMUIS A, BOCKAERT J: Central 5-11T4 receptors. Trends Pharmacol. Sci. (1995) 16:391–397.
   PubMed Web of Science ®Google Scholar
• LOVENBERG TW, BARON BM, DE LECEA L et al.: A novel adenylyl cyclase-activating serotonin receptor (5-11T7) implicated in the regulation of mammalian circadian rhythms. Neuron (1993) 11:449–458.
   Google Scholar
• EGLIN RM, JASPER JR, CHANG DJ, MARTIN GR: The 5-HT7 receptor: orphan found. Trends Pharmacol Sci. (1997) 18:104–107.
   PubMedGoogle Scholar
• HOYER D, CLARKE DE, FOZARD JR et al.: International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol. Rev. (1993) 46:157–203.
   Web of Science ®Google Scholar
• OWENS MJ, NEMEROFF CB: In: Corticotrophin-Releasing Factor. Chadwick DJ, Marsh J, Ackrill K (Eds.), John Wiley & Sons (1993) 296–316.
   Google Scholar
• NEMEROFF CB, OWENS M, BISSETTE G et al.: Reducedcorticotrophin releasing factor binding sites in the frontal cortex of suicide victims. Arch. Gen. Psychiatry (1988) 45:577–579.
   PubMed Web of Science ®Google Scholar
• HUCKS D, LOWTHER S, CROMPTON MR et al.: Corticotrophin-releasing factor binding sites in cortex of depressed suicides. Psychopharmacology (1997) 134: 174–178.
   PubMed Web of Science ®Google Scholar
• KOOB GF, BRITTON KT: In: Corticotrophin-Releasing Fac-tor: Basic and Clinical Studies of a Neuropeptide. De Souza EB, Nemeroff CB (Eds.), CRC Press (1990) 253–265.
   Google Scholar
• KALIN NH: In: Corticotrophin-Releasing Factor: Basic and Clinical Studies of a Neuropeptide. De Souza EB, Nemeroff CB (Eds.), CRC Press (1990) 275–290.
   Google Scholar
• GRIGORIADIS DE, PEARSALL D, DE SOUZA EB: Effects ofchronic antidepressant and benzodiazepine treatment on corticotrophin-releasing factor receptors in rat brain and pituitary. Neuropsychopharmacology (1989) 2:53–60.
   PubMed Web of Science ®Google Scholar
• COLE BJ, KOOB DF: In: Stress, Neuropeptides and SystemicDisease. McCubbin JA, Kaufmann PG, Nemeroff CB (Eds.), Academic Press (1991) 119–148.
   Google Scholar
• CHALMERS DT, LOVENBERG TVV, GRIGORIADIS DE et al:Corticotrophin-releasing factor receptors: from mo-lecular biology to drug design. Trends Pharmacol. Sci. (1996) 17:166–172.
   PubMedGoogle Scholar
• •A review on CRF receptors, their molecular biology and pharmacology, and their roles in a range of CNS and periph-eral disorders.
   Google Scholar
• Novel compounds with CRF antagonistic activity. Exp. Opin. Ther. Patents (1995) 5(1):55–56.
   Google Scholar
• CHEN YL, BRASELTON J, BROOKS E et al: The synthesis and SAR of non-peptide CRF antagonists. 9th RSC-SCI Medicinal Chemistry Symposium, Cambridge UK (1997). Lecture 3.
   Google Scholar
• IVERSON LL. Central actions of substance P and related tachykinins. J. Psychopharmacol. (1989) 3 (1):1–6.
   PubMedGoogle Scholar
• FDC Reports - "The Pink Sheet" (8th December 1997) 59(49):10–11.
   Google Scholar
• LEYSEN D, PINDER RM: Toward third generation antide-pressants. Ann. Reports in Med. Chem. (1994) 29:1–12.
   Google Scholar
• POST RM, CHUANG DM: In: Lithium, and the Cell: Pharma-cology and Biochemistry. Birch NJ (Ed.), (1992) 199.
   Google Scholar
• GLEITER CH, VOLZ H-P: MAO-A inhibitors: state of the art. Exp. Opin. Invest. Drugs (1996) 5 (4):409–419.
   Google Scholar
• VADNAL R, PARTHASARATHY L, PARTHASARATHY R: Role of inositol in the treatment of psychiatric disor-ders. CNS Drugs (1997) 7(1):6–16.
   Google Scholar
• LINDE K, RAMIREZ G, MULROW CD et al.: St. John's wort for depression: an overview and meta-analysis of ran-domised clinical trials. Br. Med. Journal (1996) 313:253–258.
   Google Scholar
• SCHWANINGER M, WEISBROD M, KNEPEL W: Progress indefining the mechanism of action of antidepressants: across receptors and into gene transcription. CNS Drugs (1997) 8(3):237–243.
   Google Scholar